Immunology
CD40 ligand gene therapy halts Th2-mediated tumor escape
Published in Gene Therapy Weekly, July 29th, 2004
"Tumors exhibit immune escape properties that promote their survival. These properties include modulation of Ag presentation, secretion of immunosuppressive factors, resistance to apoptosis, and induction of immune deviation, e.g, shifting from Th1- to Th2-type responses," researchers in the United States report.
"These escape mechanisms have proven to hamper several immunotherapeutic strategies, and efforts need to be taken to revert this situation. We have studied the immunological effects of introducing CD40 ligand (CD40L), a potent dendritic cell activation molecule, into the tumor...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
Source: Gene Therapy Weekly (2004-07-29)
More Articles from Gene Therapy Weekly
- Drug Resistance
Bcl-2 antisense agent G3139 invokes a response to refractory multiple myeloma - Gene Regulation
Modified nucleotides defeat barriers to RNA inaccessibility - Gene Transfer
An overnight transduction protocol prepares repopulating cells for transfer - Genetic Engineering
New compounds coax embryonic stem cells into cardiac differentiation - Bioengineering
Re-engineered coagulation factor will improve hemophilia A gene therapy - Bronchoalveolar Carcinoma
Phase II trial of GVAX lung cancer vaccine begins - More from this issue of Gene Therapy Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
